FMP

FMP

Enter

CRBP - Corbus Pharmaceutica...

Financial Summary of Corbus Pharmaceuticals Holdings, Inc.(CRBP), Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of im

photo-url-https://financialmodelingprep.com/image-stock/CRBP.png

Corbus Pharmaceuticals Holdings, Inc.

CRBP

NASDAQ

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

42.48 USD

-0.19 (-0.447%)

About

ceo

Dr. Yuval Cohen Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.corbuspharma.com

exchange

NASDAQ

Description

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the t...

CIK

0001595097

ISIN

US21833P3010

CUSIP

21833P103

Address

500 River Ridge Drive

Phone

617 963 0100

Country

US

Employee

19

IPO Date

Oct 27, 2014

Summary

CIK

0001595097

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

21833P103

ISIN

US21833P3010

Country

US

Price

42.48

Beta

2.52

Volume Avg.

244.27k

Market Cap

453.97M

Shares

-

52-Week

3.033-55.41

DCF

-1.61

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-6.16

P/B

-

Website

https://www.corbuspharma.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CRBP News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep